Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687917 | 0.93 | OPRM1 (0.47) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL4687167 | 0.92 | OPRM1 (0.46) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL1847389 | 0.92 | OPRM1 (0.48) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL4687958 | 0.91 | OPRM1 (0.46) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL4686988 | 0.91 | OPRM1 (0.49) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL4690286 | 0.91 | OPRM1 (0.45) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL4687449 | 0.91 | OPRM1 (0.47) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL4693356 | 0.91 | OPRM1 (0.45) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL14088930 | 0.91 | OPRM1 (0.45) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 | |
| SCHEMBL14088938 | 0.90 | OPRM1 (0.49) | OPRM1OPRD1OPRK1CACNA2D1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601843-B2 | 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-10-13 | — | — | US | claimed |
| US-20060270632-A1 | 4-(2-Furoyl) aminopiperidine compound useful as therapeutic agent for itching | KYORIN PHARMACEUTICAL CO., LTD NISSHIN SEIFUN GROUP INC. | 2006-11-30 | — | — | US | claimed |
| EP-2325183-A1 | 4-(2-Furoyl) Aminopiperidine compound useful as therapeutic agent for itching | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7601843-B2 | 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601843-B2 | 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601843-B2 | 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060270632-A1 | 4-(2-Furoyl) aminopiperidine compound useful as therapeutic agent for itching | KYORIN PHARMACEUTICAL CO., LTD NISSHIN SEIFUN GROUP INC. | 2006-11-30 | — | — | US | disclosed |
| EP-1621538-A1 | 4-(2-FUROYL)AMINOPIPERIDINE COMPOUND USEFUL AS THERAPEUTIC AGENT FOR ITCHING | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270632-A1 | 4-(2-Furoyl) aminopiperidine compound useful as therapeutic agent for itching | HRH4, HRH3, HRH2 | OPRM1 249/4885OPRD1 321/4885OPRK1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.